June 14, 2022
RFA-HL-21-013 - Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)
National Heart, Lung, and Blood Institute (NHLBI)
This Notice is to inform the research community that NHLBI is expiring RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)" effective immediately. Potential applicants are advised to regularly check the NIH Guide and/or the NHLBI web page for related funding opportunity announcements.
Antonello Punturieri, MD, PhD
Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0233
Email: [email protected]